Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 4Unknown 2Terminated 1

Sponsor Class

OTHER 2NIH 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Burkitt Lymphoma 1

Interventions

Cisplatin 352Oxaliplatin 262Capecitabine 258Radiotherapy 240Gemcitabine 223Docetaxel 223Carboplatin 223Cyclophosphamide 219Drug Therapy 218Paclitaxel 205apatinib 201Bevacizumab 195camrelizumab 190Fluorouracil 187sintilimab 133Blood Specimen Collection 125Irinotecan 124Dexamethasone 123Etoposide 119Radiosurgery 118toripalimab 117Surgical Procedures, Operative 115pembrolizumab 110Pemetrexed 108anlotinib 105S 1 (combination) 105Surveys and Questionnaires 101Leucovorin 101Nivolumab 98tislelizumab 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × OTHER × epratuzumab × Clear all
NCT01279707 2014-07-14

MARALL

Queen Mary University of London

Phase 1/2 Unknown
55 enrolled
Lymphoid

Burkitt Lymphoma, Recurrence

NCT01354457 2014-06-25

RIT 90YEpra

Nantes University Hospital

Phase 1/2 Unknown
21 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡